LCZ696I
Total Payments
$41,947
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $41,947 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41,947 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED PATIENT AND INVESTIGATOR-BLINDED STUDY TO EXPLORE THE EFFICACY OF ORAL SACUBITRIL/VALSARTAN IN ADULT PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (NHCM) | Novartis Pharmaceuticals Corporation | $41,947 | 0 |
Top Doctors Receiving Payments for LCZ696I
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $41,947 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $41,947
- Total Doctors 0
- Transactions 5
About LCZ696I
LCZ696I is a drug associated with $41,947 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $41,947 was paid across 5 transactions to 0 doctors.
The most common payment nature for LCZ696I is "Unspecified" ($41,947, 100.0% of total).
LCZ696I is associated with 1 research study, including "A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED PATIENT AND INVESTIGATOR-BLINDED STUDY TO EXPLORE THE EFFICACY OF ORAL SACUBITRIL/VALSARTAN IN ADULT PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (NHCM)" ($41,947).